Great minds with great ideas usually share in the midst of their persecution" - Jeremy Aldana
Today, we look at a small antibiotic concern. This 'busted IPO' comes from across the pond and recently received FDA approval for its primary drug candidate. We provide an in-depth 'deep dive' in the paragraphs below.
Company Overview
Nabriva Therapeutics plc (NBRV) is a Dublin, Ireland-based biopharmaceutical concern focused on the development of antibiotics to treat serious infections. The company has two primary assets. One (Xenleta) received FDA approval on August 19, 2019; for the other